'Stuffed': users of supplementary patented components in drug combos can be sued - European court
This article was originally published in Scrip
A recent decision from the Court of Justice of the European Union has shed more light on the messy regulations governing supplementary protection certificates (which give five years extra IP protection) and the use of certificated-protected components in combination products.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.